Novo Nordisk strikes second licensing deal since frosty capital-markets day

Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.

Source:MarketWatch
Disclaimer:Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.